Skip to Content
MilliporeSigma

Skip To

SML1457

Lonafarnib

≥98% (HPLC), farnesyl transferase inhibitor, powder

Synonym(s):

4-[2-[4-[(11R)-3,10-Dibromo-8-chloro-6,11-dihydro-5Hbenzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, SCH-66336, SCH66336

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Size/SKUAvailabilityPrice
5 mg

Available to ship TODAYfromMILWAUKEE

$148.00
25 mg

Available to ship TODAYfromMILWAUKEE

$535.00

About This Item

Empirical Formula (Hill Notation):
C27H31Br2ClN4O2
CAS Number:
Molecular Weight:
638.82
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder

$148.00


Available to ship TODAYDetails


Request a Custom Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Lonafarnib, ≥98% (HPLC)

Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

−20°C

SMILES string

O=C(N)N(CC1)CCC1CC(N2CCC([C@H]3C(N=CC(Br)=C4)=C4CCC5=C3C(Br)=CC(Cl)=C5)CC2)=O

InChI

1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1

InChI key

DHMTURDWPRKSOA-RUZDIDTESA-N

Gene Information

General description

Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI). K- and N-Ras are substrates of farnesyl transferase.

Biochem/physiol Actions

Lonafarnib is a potent inhibitor of farnesyltransferase, an enzyme responsible for a post-translational modification of proteins (including Ras) that gives a protein sufficient hydrophobicity to translocate to the plasma membrane. Farnesylation regulates signaling cascades controlling cell survival, proliferation and differentiation, so variety of possible uses is not surprising a post-translational modification of proteins (including Ras) that gives a protein sufficient hydrophobicity to translocate to the plasma membrane. Lonafarnib has been studies for possible treatment of progeria, various cancers, and hepatitis D.
Lonafarnib is a potent inhibitor of farnesyltransferase.
Lonafarnib prevents the post-translational lipid modification of H-Ras and other farnesylated proteins. Lonafarnib treatment results in microtubule bundling, increased microtubule acetylation and stabilization and suppression of microtubule dynamics.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML2898L9664Y0000604
description

≥98% (HPLC)

description

≥98% (HPLC)

description

≥98% (HPLC), powder

description

European Pharmacopoeia (EP) Reference Standard

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

-

form

powder

form

powder

form

powder

form

-

Quality Level

100

Quality Level

100

Quality Level

200

Quality Level

-

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: 5 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: soluble 50 mg/mL, H2O: insoluble

solubility

-

color

white to beige

color

white to beige

color

white

color

-


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Questions

Reviews

No rating value

Active Filters